

---

**EU RMP Addendum**

Drug Substance	ChAdOx1-S (recombinant) AZD1222
EU RMP Version Number	1
Addendum Version Number	1
Addendum Succession Number	1
Date	21 December 2020

---

---

## **Country Specific Addendum to the EU RISK MANAGEMENT PLAN (RMP) FOR COVID-19 VACCINE ASTRAZENECA (ChAdOx1-S [RECOMBINANT] in UNITED KINGDOM**

---

Plan Approved by:

**Name Redacted**

(UKMC Medical Director)

**Name Redacted**

(UKMC Patient Safety Lead)

Note: COVID-19 Vaccine AstraZeneca will be referred to by its development number (AZD1222) throughout this addendum

This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.